



Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

CAMBRIDGE, Mass., Oct. 1 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that two abstracts on IDX184, the company's lead hepatitis C development program, have been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, October 30-November 3, 2009 in Boston, Massachusetts). Full abstracts can now be viewed at the AASLD website at www.aasld.org.

The accepted abstracts are as follows:

- Lalezari, et al, "Antiviral Activity, Safety and Pharmacokinetics of IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor, in Patients with Chronic Hepatitis C", will be presented in a late-breaking poster session on Monday, November 2 between 8:00 a.m. - 5:30 p.m.
- Lалlos, et al, "Combination of IDX184, a Nucleotide Prodrug Polymerase Inhibitor, With Other Classes of HCV Inhibitors is Additive to Synergistic in the HCV Replicon In Vitro" will be presented in a poster session entitled HCV Therapy: Preclinical and Clinical Development on Tuesday, November 3, 2009 between 8:00 a.m. - 1:00 p.m.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "will" or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on third party collaborators, changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Idenix Pharmaceuticals Contact:
Teri Dahlman (617) 995-9905

SOURCE Idenix Pharmaceuticals, Inc.

Teri Dahlman of Idenix Pharmaceuticals, +1-617-995-9905